The firm currently offers a multi-cancer detection test as an opt-in for patients receiving its Shield colorectal cancer screening assay.

The firms will integrate their technologies into a single workflow and jointly engage in initiatives to raise awareness of AI-based precision oncology testing.

The test is intended to support rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings.

The aim of the competition is to accelerate the creation of tests that enable early detection and diagnosis, particularly in less common cancers ...

The mass spectrometry-based test is intended as an aid in evaluating individuals with signs of cognitive impairment for the amyloid brain pathology associated with Alzheimer's.

NEW YORK – Avricore Health subsidiary HealthTab announced on Thursday that it has signed an agreement with Abbott to supply and distribute the firm's point-of-care testing products in the UK.

The firm recently raised $15 million in seed financing to further validate and commercialize its pathogen detection and antimicrobial resistance profiling platform.

Analysts for the banks noted the large addressable market for the company's cancer screening tests as well as the benefits of its commercialization deals with Abbott and Roche.

NEW YORK – AmoyDx announced on Monday that it has received approval from Japan's Ministry of Health, Labour and Welfare for the AmoyDx Pan Lung Cancer PCR Panel as a companion diagnostic for Nippon ...

According to CEO Wesley Sukdao, Proteotype is also gearing up to raise about £5 million and seeking a lead investor.